Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 10/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.49 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.49 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | PI4KA | P42356 | 1/20 | 0.49 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.49 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.49 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15456117 | 0.94 | P2RY12 (0.51) | P2RY12P2RX1P2RX3P2RX4RXFP1 | |
| SCHEMBL14372074 | 0.90 | P2RY12 (0.52) | P2RY12P2RX1P2RX3P2RX4RXFP1 | |
| SCHEMBL21504639 | 0.89 | PI4KA (0.52) | P2RY12PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL29444514 | 0.89 | PI4KA (0.62) | P2RY12ALDH1A1LMNARXFP1PI4KA | |
| SCHEMBL1097616 | 0.89 | PI4KA (0.62) | P2RY12ALDH1A1LMNARXFP1PI4KA | |
| SCHEMBL16378775 | 0.89 | PI4KA (0.62) | P2RY12ALDH1A1LMNARXFP1PI4KA | |
| SCHEMBL30827092 | 0.89 | PI4KA (0.62) | P2RY12ALDH1A1LMNARXFP1PI4KA | |
| SCHEMBL22601403 | 0.89 | PI4KA (0.62) | P2RY12ALDH1A1LMNARXFP1PI4KA | |
| SCHEMBL22402681 | 0.89 | PI4KA (0.62) | P2RY12ALDH1A1LMNARXFP1PI4KA | |
| SCHEMBL26937492 | 0.89 | PI4KA (0.52) | P2RY12PI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070258921-A1 | PROCESS FOR DEPIGMENTING THE SKIN | L'OREAL (FR) | 2007-11-08 | — | — | US | disclosed |
| US-20070237734-A1 | ANTI-WRINKLE COSMETIC COMPOSITION | L'OREAL (FR) | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070258921-A1 | PROCESS FOR DEPIGMENTING THE SKIN | TYR, CUTA, NQO1 | P2RY12 4111/4885ALDH1A1 303/4885P2RX1 4123/4885 |
| US-20070237734-A1 | ANTI-WRINKLE COSMETIC COMPOSITION | ADORA2A, ADORA3, ADORA1 | P2RY12 329/4885ALDH1A1 834/4885P2RX1 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.